Hepatic effects of GLP-1 mimetics in diabetic milieu: A mechanistic review of involved pathways

Yaribeygi H., Kashian K., Moghaddam K. I., Karim S. R., Bagheri N., KARAV S., ...More

Journal of Diabetes and its Complications, vol.39, no.1, 2025 (SCI-Expanded) identifier identifier

  • Publication Type: Article / Review
  • Volume: 39 Issue: 1
  • Publication Date: 2025
  • Doi Number: 10.1016/j.jdiacomp.2024.108928
  • Journal Name: Journal of Diabetes and its Complications
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, BIOSIS, CINAHL, MEDLINE
  • Keywords: Diabetes mellitus, GLP-1, Hepatic disorder, Inflammation, Liver, NAFLD, Oxidative stress
  • Çanakkale Onsekiz Mart University Affiliated: Yes

Abstract

Patients with diabetic are at a higher risk of developing hepatic disorders compared to non-diabetic individuals. This increased risk can be attributed to the diabetic environment, which triggers and exacerbates harmful pathways involved in both diabetic complications and hepatic disorders. Therefore, it is important to consider the use of antidiabetic agents that offer benefits beyond glycemic control and have positive effects on liver tissues. Glucagon-like peptide-1 (GLP-1) mimetics are a novel class of antidiabetic medications known for their potent blood sugar-lowering effects. Emerging evidence suggests that these drugs also have favorable effects on the liver. However, the precise effects and underlying mechanisms are not yet fully understood. In this review, we aim to provide a mechanistic perspective on the liver benefits of GLP-1 mimetics and outline the mediating mechanisms involved.